These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 37799636)

  • 41. An on-site community-based model for hepatitis C screening, diagnosis, and treatment among people who inject drugs in Kerman, Iran: The Rostam study.
    Mirzazadeh A; Hosseini-Hooshyar S; Shahesmaeili A; Sharafi H; Shafiei M; Zarei J; Mousavian G; Tavakoli F; Ghalekhani N; Shokoohi M; Khezri M; Mehmandoost S; Shojaei MR; Karamouzian M; Briceno A; Morris MD; Alavian SM; Haghdoost AA; Sharifi H; Page KA
    Int J Drug Policy; 2022 Apr; 102():103580. PubMed ID: 35074607
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia.
    Iversen J; Dore GJ; Catlett B; Cunningham P; Grebely J; Maher L
    J Hepatol; 2019 Jan; 70(1):33-39. PubMed ID: 30367897
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Estimating the Consensus hepatitis C Cascade of Care among people who inject drugs in Australia: Pre and post availability of direct acting antiviral therapy.
    Iversen J; Dore GJ; Starr M; Catlett B; Cunningham P; Geddes L; Maher L
    Int J Drug Policy; 2020 Sep; 83():102837. PubMed ID: 32645585
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting?
    Gountas I; Sypsa V; Anagnostou O; Martin N; Vickerman P; Kafetzopoulos E; Hatzakis A
    Addiction; 2017 Jul; 112(7):1290-1299. PubMed ID: 28107585
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study.
    Solomon SS; Mehta SH; Srikrishnan AK; Solomon S; McFall AM; Laeyendecker O; Celentano DD; Iqbal SH; Anand S; Vasudevan CK; Saravanan S; Lucas GM; Kumar MS; Sulkowski MS; Quinn TC
    Lancet Infect Dis; 2015 Jan; 15(1):36-45. PubMed ID: 25486851
    [TBL] [Abstract][Full Text] [Related]  

  • 46. "We don't need services. We have no problems": exploring the experiences of young people who inject drugs in accessing harm reduction services.
    Krug A; Hildebrand M; Sun N
    J Int AIDS Soc; 2015; 18(2 Suppl 1):19442. PubMed ID: 25724510
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Barriers to accessing sterile injecting equipment for people who inject drugs: An integrative review.
    Lawson E; Walthall H
    J Clin Nurs; 2023 Aug; 32(15-16):4502-4514. PubMed ID: 36068712
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Time-to-hepatitis C treatment initiation among people who inject drugs in Melbourne, Australia.
    Aung PTZ; Spelman T; Wilkinson AL; Dietze PM; Stoové MA; Hellard ME
    Epidemiol Infect; 2023 May; 151():e84. PubMed ID: 37157844
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A transient positive association between direct-acting antiviral therapy for hepatitis C infection and drug-related hospitalization among people who inject drugs: Self-controlled case-series analysis of national data.
    McDonald SA; Hickman M; Dillon JF; Yeung A; McAuley A; Fraser A; Hayes PC; Hutchinson SJ
    Addiction; 2024 Feb; 119(2):369-378. PubMed ID: 37726951
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Optimal hepatitis C treatment adherence patterns and sustained virologic response among people who inject drugs: The HERO study.
    Heo M; Norton BL; Pericot-Valverde I; Mehta SH; Tsui JI; Taylor LE; Lum PJ; Feinberg J; Kim AY; Arnsten JH; Sprecht-Walsh S; Page K; Murray-Krezan C; Anderson J; Litwin AH;
    J Hepatol; 2024 May; 80(5):702-713. PubMed ID: 38242324
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Outcomes of Real-World Integrated HCV Microelimination for People Who Inject Drugs: An expansion of the Punjab Model.
    Dhiman RK; Grover GS; Premkumar M; Roy A; Taneja S; Duseja A; Arora S;
    EClinicalMedicine; 2021 Nov; 41():101148. PubMed ID: 34712928
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 'Treat my whole person, not just my condition': qualitative explorations of hepatitis C care delivery preferences among people who inject drugs.
    Tsui JI; Barry MP; Austin EJ; Sweek EW; Tung E; Hansen RN; Ninburg M; Scott JD; Glick SN; Williams EC
    Addict Sci Clin Pract; 2021 Aug; 16(1):52. PubMed ID: 34384494
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Age-Related Differences in Past or Present Hepatitis C Virus Infection Among People Who Inject Drugs: National Human Immunodeficiency Virus Behavioral Surveillance, 8 US Cities, 2015.
    Abara WE; Trujillo L; Broz D; Finlayson T; Teshale E; Paz-Bailey G; Glick S; Al-Tayyib AA; Robinson WT; Masiello-Schuette S; Sey EK; Anderson BJ; Poe J; Braunstein S
    J Infect Dis; 2019 Jul; 220(3):377-385. PubMed ID: 30915477
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study.
    Grebely J; Alavi M; Micallef M; Dunlop AJ; Balcomb AC; Phung N; Weltman MD; Day CA; Treloar C; Bath N; Haber PS; Dore GJ;
    Addiction; 2016 Feb; 111(2):311-9. PubMed ID: 26451534
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reviewing harm reduction for people who inject drugs in Asia: the necessity for growth.
    Stone KA
    Harm Reduct J; 2015 Oct; 12():32. PubMed ID: 26472335
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Maintaining the healthy body: Blood management and hepatitis C prevention among men who inject performance and image-enhancing drugs.
    Fomiatti R; Lenton E; Latham JR; Fraser S; Moore D; Seear K; Aitken C
    Int J Drug Policy; 2020 Jan; 75():102592. PubMed ID: 31855731
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The impact of pluralistic ignorance on the provision of health care for people who inject drugs.
    Brener L; von Hippel C; Horwitz R; Hamwood J
    J Health Psychol; 2015 Sep; 20(9):1240-9. PubMed ID: 24271692
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Staying hepatitis C negative: A systematic review and meta-analysis of cure and reinfection in people who inject drugs.
    Latham NH; Doyle JS; Palmer AY; Vanhommerig JW; Agius P; Goutzamanis S; Li Z; Pedrana A; Gottfredsson M; Bouscaillou J; Luhmann N; Mazhnaya A; Altice FL; Saeed S; Klein M; Falade-Nwulia OO; Aspinall E; Hutchinson S; Hellard ME; Sacks-Davis R
    Liver Int; 2019 Dec; 39(12):2244-2260. PubMed ID: 31125496
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Concordance between self-reported and current hepatitis C virus infection status in a sample of people who inject drugs in Sydney and Canberra, Australia.
    Gibbs D; Grebely J; Sutherland R; Larney S; Butler K; Dietze PM; Starr M; Peacock A
    Drug Alcohol Rev; 2021 Nov; 40(7):1349-1353. PubMed ID: 33759276
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Directly observed therapy of chronic hepatitis C with ledipasvir/sofosbuvir in people who inject drugs at risk of nonadherence to direct-acting antivirals.
    Schütz A; Moser S; Schwanke C; Schubert R; Luhn J; Gutic E; Lang T; Schleicher M; Haltmayer H; Gschwantler M
    J Viral Hepat; 2018 Jul; 25(7):870-873. PubMed ID: 29316001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.